Supramolecular lipidic drug delivery systems: From laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B

Advanced Drug Delivery Reviews

Volumn 24, Issue 2-3, 1997, Pages 345-363

  Hillery, Anya M ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Abelcet(TM); AmBisome(TM); Amphocil(TM); amphotericin B; drug delivery systems; fungal infections; liposomes

Indexed keywords

ANTIBIOTICS; BIOMEDICAL ENGINEERING; DRUG PRODUCTS; DRUG THERAPY; LIPIDS; MORPHOLOGY; PATIENT TREATMENT; PHARMACOKINETICS; TOXICITY;

ABELCET; AMBISOME; AMPHOTERICIN; BIODISTRIBUTION; DRUG TOXICITY; FUNGAL INFECTION; LIPOSOMES; SUPRAMOLECULAR LIPIDIC DRUG DELIVERY SYSTEM;

CONTROLLED DRUG DELIVERY;

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL; CHOLESTEROL SULFATE SODIUM; DEOXYCHOLIC ACID; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDIC ACID; LIPID; LIPOSOME; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; MORPHOLOGY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0343376089     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00496-6     Document Type: Conference Paper

References (113)

1. Gregoriadis, G. (Ed.) (1993) Liposome Technology: Liposome Preparation and Related Techniques. Vol. 1, 2nd edition, CRC Press, Boca Raton, FL.
2. Bangham, A.D., Standish, M.M. and Watkins J.C. (1965) Diffusion of univalent ions across lamellae of swollen phospholipids. J. Mol. Biol. 13, 238-252.
3. Florence, A.T. and Gregoriadis, G. (1991) Targeting peptides and proteins: NATO ASI. Trends Biotechnol. 9, 295-297.
4. Sarosi, G.A. (1990) Amphotericin B: still the "gold standard" for antifungal therapy. Postgrad. Med. 88, 151-166.
5. Meyer, R.D. (1992) Current role of therapy with amphotericin B. Clin. Infect. Dis. 14, S154-S160.
6. Carr, M. and Dismukes, W.E. (1992) Antifungal agents. In: J.L. Gorbach, J.G. Barlett and N.R. Blacklow (Eds), Infectious Diseases, WB Saunders, Philadelphia, pp. 306-313.
7. Aisner, J., Schimpff, S.C. and Wiernik, P.H. (1977) Treatment of invasive aspergillosis. Relationship of early diagnosis and treatment to response. Ann. Intern. Med. 90, 539-543.
8. Gold, W., Stout, H.A., Pagona, J.F. and Donovick, R. (1955) Amphotericins A and B: antifungal antibiotics produced by a streptomycete. Antibiotics Annual, 1955-1956, 579-586.
9. Bolard, J. (1986) How do polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864, 257-304.
10. De Kruijff, B. and Demel, R.A. (1974) Polyene antibiotic sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim. Biophys. Acta 339, 57.
11. Warnock, D.W. (1991) Amphotericin B: an introduction. J. Antimicrob. Chemother. 28 (Suppl. B). 27-38.
12. Palacios, J. and Serrano, R. (1978) Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast. FEBS Lett. 91, 198-201.
13. Brajtburg, J., Powderly, J.W.G., Kobayashi, G.S. and Medoff, G. (1990) Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34. 183-188.
14. Bolard, J., Joly, B. and Yeni, P. (1993) Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems. J. Liposome Res. 3, 409-428.
15. Witzke, N. and Bittman, R. (1984) Dissociation kinetics and equilibrium binding properties of polyene antibiotic complexes with phosphatidylcholine/sterol vesicles. Biochemistry 23, 1668-1674.
16. Kerridge, D. (1986) Mode of action of clinically important antifungal drugs. Adv. Microb. Physiol. 27, 1-64.
17. Fromtling, R.A. (1993) Amphotericin B cholesteryl sulfate complex. Drugs Future 18, 303-306.
18. Barriere, S.L. (1990) Pharmacology and pharmacokinetics of traditional systemic antifungal agents Pharmacotherapy 10 (Suppl.), 134-140.
19. Utz, J.P. (1964) Amphotericin B toxicity: general side effects. Ann. Intern. Med. 61, 340.
20. Reynolds, J.E.F. (Ed.) Martindale: The Extra Pharmacopoeia. (1993) 30th edition. The Pharmaceutical Press, London, pp. 315-319.
21. McCurdy, D.K., Frederic, M. and Elkinton, J.R. (1968) Renal tubular acidosis due to amphotericin B. New Engl. J. Med. 278, 124.
22. Sabra, R. and Branch, R.A. (1990) Amphotericin B nephrotoxicity. Drug Safety 5, 94-108.
23. Gallis, H.G., Drew, R.H. and Packard, W.W. (1990) Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308-329.
24. Bodey, G., Bueltmann, B. and Duguid, W. (1992) Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis. 11, 99-109.
25. Gregoriadis, G. (1976) The carrier potential of liposomes in biology and medicine. New Engl. J. Med. 295, 704-710.
26. |26] Tanaka, T., Taneda, K. and Kobayashi, H. (1975) Application of liposomes to the pharmaceutical modification of the distribution characteristics of drugs in the rat. Chem. Pharm. Bull. (Tokyo) 23, 3069-3074.
27. Hoekstra, D. and Scherphof, G. (1979) Effect of fetal calf serum and serum protein fraction on the uptake of liposomal phosphatidylcholine by rat hepatocytes in primary monolayer culture. Biochim. Biophys. Acta 551, 109-121.
28. Lasic, D.D. (1995) Doxorubicin in sterically stabilized liposomes Nature 380, 561-562.
29. Senior, J. and Gregoriadis, G. (1982) Is the half-life of circulating small unilamellar liposomes determined by changes in their permeability? FEBS Lett. 145, 109-114.
30. Scherpof, G., Damen, J. and Wilschut, J. (1984) Interactions of liposomes with plasma proteins, In: Gregoriadis, G. (Ed.), Liposome Technology. Vol. 3, CRC Press, Boca Raton, FL, pp. 205-224.
31. Papahadjopoulos, D., Cowden, M. and Kimelberg, H. (1973) Role of cholesterol in membranes. Effects of phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim. Biophys. Acta 33, 8-26.
32. Gregoriadis, G. and Davis, C. (1979) Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem. Biophys. Res. Commun. 89, 1287-1293.
33. Kirby, C., Clarke, J. and Gregoriadis, G. (1980) Effect of the cholesterol content of small unilamellar liposomes on their stability in vitro and in vivo. Biochem. J. 186, 591-598.
34. New, R.R.C., Chenace, M.L. and Heath, S. (1981) Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8, 371-381.
35. Taylor, R.L., Williams, D.M., Craven, P.C., Graybill, J.R., Drutz, D.J. and Magee, W.E. (1982) Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am. Rev. Respir. Dis. 125, 610-611.
36. Graybill, J.R., Craven, P.C., Taylor, R.L., Williams, D.M. and Magee, W.E. (1982) Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145, 748-752.
37. Lopex-Berestein, G., Mehta, R., Hopfer, R., Mills, K., Kasi, L., Mehta K., Fainstien, V., Luna, W., Hersh, E.M. and Juliano, R.L. (1983) Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin B. J. Infect. Dis. 147, 939-945.
38. Aherns, J., Graybill, J.R., Craven, P.C. and Taylor, R.L. (1984) Treatment of experimental murine candidiasis with liposome associated amphotericin B. J. Med. Vet. Mycol. 22, 163.
39. Hopfer, R.L., Mills, K., Mehta, R., Lopez-Berestein, G., Fainstien, V. and Juliano, R.L. (1984) In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25, 287-389.
40. Juliano, R.L., Grant, C.W., Barber, K.R. and Kaop, M.A. (1987) Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31, 1-11.
41. Szoka, F.C., Jr., Milholland, D. and Barza, M. (1987) Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31, 421-429.
42. Mehta, R., Hsu, M.J., Juliano, R.L., Kranse, H.J. and Regen, S.L. (1986) Polymerized phospholipid vesicles containing amphotericin B: evaluation of toxic and antifungal activities in vitro. J. Pharm. Sci. 75, 579-581.
43. Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M.P., Keating, M., Rosenblum, M.G., Mehta, R., Luna, M., Hersh, E.M., Reuben, J., Juliano, R.L. and Bodey, G.P. (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151, 704-710.
44. Lopez-Berestein, G , Bodey, G.P., Frankel, L.S. and Mehta, K. (1987) Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J. Clin. Oncol. 5, 310-317.
45. Weber, R.S. and Lopez-Berestein, G. (1987) Treatment of invasive Aspergillus sinusitis with liposomal amphotericin B. Laryngoscope 97, 937-941.
46. Sculier, J.P., Coune, A., Meunier, F., Brassinne, C., Laduran, C., Hollaert, C., Collette, N., Heymans, C. and Klastersky, J. (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Clin. Oncol. 24, 527-538.
47. Alder-Moore, J. and Proffitt, T. (1993) Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3, 429-450.
48. Gamble, R.C. (1988) Method for preparing small vesicles using microemulsification, US Patent No 4, 753, 788.
49. Data on file, NeXstar Inc.
50. Anaissie, E., Ho, D. and Paetznick, V. (1990) Comparative in vitro activities of liposomal amphotericin B and amphotericin B against 104 clinical yeast isolates from a large cancer center. In: Abstracts of the 90th Annual Meeting of the American Society for Microbiology, A-113. American Society for Microbiology, Washington, DC.
51. Alder-Moore, J.P., Fujii, G. and Lee, M.A. (1993) In vitro and in vivo interactions of AmBisome with pathogenic fungi. J. Liposome Res. 3, 151-156.
52. Vanetten, E.W.M., Chander, H.R., Snijders, S.V. and Bakker-woudenberg, L.A.J.M. (1995) Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. J. Antimicrob. Chemother. 36, 961-974.
53. Proffitt, R.T., Sartorius, A., Chiang, S.M., Sullivan, L. and Adler-Moore, J.P. (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl B). 49-61.
54. Lee, J.W., Amantea, M.A., Francis, P.A., Navarro, E.E., Bacher, J., Pizzo, P.A. and Walsh, T.J. (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38, 713-718.
55. Hospenthal, D.R., Rogers, A.L. and Beneke, E.S. (1989) Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob. Agents Chemother. 33, 16-18.
56. Tollemar, J. and Ringden, O. (1992) Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome). Drug Invest. 4, 232-238.
57. Adler-Moore, J. (1993) In vitro and in vivo evidence for reduced toxicity and mode of action of AmBisome. Bone Marrow Transpl. 12 (Suppl. 4), S146.
58. Adler-Moore, J., Fujii, G., Lee, M.J.A., Frank, K. and Darl, S. (1993) Fluorescence and electron microscopic elucidation of the interaction of liposomal amphotericin B (AmBisome) and pathogenic fungi. 33rd Intersci. Conf. Antimicrob. Agents Chemother. 256, A746. American Society for Microbiology, Washington, DC.
59. Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M.A., Gorin, N.C., Klastersky J. and Fenaux, P. (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome), in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28 (Suppl. B), 73-82.
60. Mills, W., Chopra, R., Linch, D.C. and Goldstone, A.H. (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropaenic patients: a single-centre experience of 133 episodes in 116 patients. Br. J. Haematol. 86, 754-760.
61. Gibson, G., Richens, D., Hood, J., Balfour, A., Naik, S. and Wheatley, D. (1994) Treatment of invasive aspergillosis in cardiac transplant recipients with Liposomal Amphotericin. British Transplantation Society Meeting, Portsmouth, 12-13 April.
62. Ng, T.T.C. and Denning, D.W. (1995) Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections -evaluation of UK compassionate use data. Arch. Intern. Med. 155, 11093-11098.
63. Schurmann, D., Marques, B.D., Grunewald, T., Pohle, H.D., Hahn, H. and Ruf, B. (1991) Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J. Infect. Dis. 164, 620-622.
64. Tollemar, J., Ringdean, O., Anderson, B., Sundberg, B., Ljungman, P., Sparrelid, E. and Tyden, G. (1993) Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections in neutropaenic patients: a single-centre experience of 133 episodes in 116 patients. Transpl. Proc. 25, 1495-1497.
65. Fisher, E.W., Toma, A., Fisher, P.H. and Cheesman, A.D. (1991) Rhinocerebral mucormycosis: use of liposomal amphotericin B. J. Laryngol. Otol. 105, 575-577.
66. Vivani, M.A., Cofrancesco, E., Boschetti, C., Tortorano, A.M. and Cartellaro, M. (1991) Eradication of Fursarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses. 34, 255-256.
67. Davidson, R.N., Croft, S.L., Scott, A.G., Maini, M., Moody, A.H. and Bryceson, A.D.M. (1991) Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet 337, 1061-1062.
68. Meunier, F., Prentice, H.G. and Ringden, O. (1991) Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob. Chemother. 28 (Suppl. B), 83-91.
69. Ringden, O., Andstrom, E., Remberger, M., Svahn, B.M. and Tollemar, J. (1994) Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transpl. 14 (Suppl. 5), S10-S14.
70. Ringden, O. and Tollemar, J. (1993) Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mycoses 36, 187-192.
71. Lackner, H., Schwinger, W., Urban, C., Muller, W., Ritschl, E., Reiterer, F., Kuttnighaim, M., Urlesberger, B. and Hauer, C. (1992) Liposomal amphotericin B for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics 89, 1259-1261.
72. Jarlov, J.O., Born, P. and Bruun, B. (1995) Candida-albicans meningitis in a 27 weeks premature infant treated with liposomal amphotericin B (AmBisome). Scand. J. Infect. Dis. 27, 419-420.
73. Janoff, A.S., Boni, L.T., Popescu, M.C., Ninchey, S.R., Cullis, P.R., Madden, T.D., Taraschi, T., Gruner, S.M., Shyamsunder, E., Tate, M.W., Mendelson, R. and Bonner, D. (1988) Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85, 6122.
74. Perkins, W.R., Minchey, S.R., Boni, L.T., Swenson, C.E., Popescu, M.C., Pasternack, R.F. and Janoff, A.S. (1992) Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107, 271-282.
75. Janoff, A.S., Perkins, W.R., Saleton, S.L. and Swenson, C.E. (1993) Amphotericin B Lipid Complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 3, 451-472.
76. Clark, J.M., Whitney, R.R., Olsen, S.J., George, R.J., Swerdel, M.R., Kunselman, L. and Bonner, D.P. (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35, 615-621.
77. Olsen, S.J., Swerdel, M.R., Blue, B. et al (1991) Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43, 831-835.
78. Lee, J.W., Allende, M., Amantea, M., Francis, P., Peter, J., Thomas, V., Francesconi, A., Lyman, C., Schaufele, R., Bacher, J., Pizzo, P. and Walsh, T. (1991) Pharmacokinetics and efficacy of amphotericin B lipid complex (ABLC) against chronic disseminated candidiasis in rabbits. 31st Intersci. Conf. Antimicrob. Agents Chemother. A579. American Society for Microbiology, Washington, DC.
79. Data on file, The Liposome Company Inc.
80. Janknegt, R., de Marie, S., Bakker-Woudenberg, I.A.J.M. and Crommelin, D.J.A. (1992) Liposomal and lipid formulations of amphotericin B. Clin. Phamacokinet. 23, 279-291.
81. Kan, V., Bennett, J., Amanthea, M., Smolskis, M., McManus, E., Grasela, D. and Sherman, J.W., (1991) Comparative safety, tolerance and pharmacokinetics of amphotericin B lipidic complex and amphotericin B deoxycholate in healthy young male volunteers. J. Infect. Dis. 164, 418-425.
82. DeWill, S., Rossi, C., Duchteau, J., Braitman, A., Gupta, R. and Clumeck, N. (1991) Safety, tolerance and immuno-modulatory effect of amphotericin B lipid complex (ABLC) in HIV infected subjects. Phase I/II study. 31st Intersci. Conf. Antimicrob. Agents Chemother. A288. American Society for Microbiology, Washington, DC.
83. Mehata, R., Lopez-Berestein, G., Hopfer, R., Mills, K. and Juliano, R.L. (1984) Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta 770, 230-234.
84. Barwicz, J., Gareau, R., Audet, A., Morisset, A., Villiard, J. and Gruda, I. (1991) Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem. Biophys. Res. Commun. 181, 722-728.
85. Barwicz, J., Christian, S. and Gruda, I. (1992) Effects of the aggregation state of amphotericin B on toxicity to mice. Antimicrob. Agents Chemother. 36, 2310-2315.
86. Wasan, K.M., Brazeau, G.A., Keyhani, A., Hayman, A.C. and Lopez-Berestein, J.G. (1993) Role of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37, 246-250,
87. Kline, S., Larsen, T.A., Fieber, L., Fishbach, R., Greenwood, M., Harris, R., Kline, M.W., Tennican, P.O. and Janoff, E.N. (1995) Limited toxicity of prolonged therapy with high doses of amphotericin B-lipid complex. Clin. Infect. Dis. 1, 1154-1158.
88. Oravcova, E., Mistrik, M., Sakalova, A., Drgona, L. Kollar, T., Helpianska, L., Ilavska, I., Sorkovska, D., Spanik, S., Kukuckova, E. and Krcmery, V. (1995) Amphotericin B-lipid complex to treat invasive fungal infections in cancer patients - report of efficacy and safety in 20 patients. Chemotherapy 41, 473-476.
89. Walsh, T.J., Hiemenz, J.W., Seibel, N. and Anaissie, E.J. (1994) Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. 34th Intersci. Conf. Antimicrob. Agents Chemother. AM69. American Society for Microbiology, Washington, DC.
90. Bow, E.J. (1994) Safety and efficacy of amphotericin B lipid complex (ABLC) in systemic candidiasis. 8th Int. Symp. Infect. Immunocomp. Host. Davos, Switzerland, 19-22 June.
91. Sharkey, P.K., Lipke, R., Renteria, A., Galgiani, J., Catanzaro, A., Diaz, M., Kramer, M., Whitney, R. and Gupta, R. (1991) Amphotericin B lipidic complex (ABLC) in treatment of coccidioidomycosis. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, A742. American Society for Microbiology, Washington, DC.
92. Hiemenz, J.W., Seibel, T. and Walsh, T. (1994) Safety and efficacy of amphotericin B lipid complex (ABLC) in neutropenic patients with life-threatening mycoses. Ann. Oncol. 5 (Suppl. 8), A P1017.
93. Wingard, J.R. and Walker, R.C. (1994) Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses. Blood 84 (Suppl. 1), A1928.
94. Patterson, T.F., Miniter, P., Dijkastra, J., Szoka, F.C., Ryan, J. and Andriole, V.T. (1989) Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol sulfate complexes. J. Infect. Dis. 159, 717-724.
95. Guo, L.S.S., Fielding, R.M., Lasic, D.D., Hamilton, R.L. and Mufuson, D. (1991) Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulphate discs. Int. J. Pharm. 75, 45-54.
96. Guo, L.S.S. and Working, P.K. (1993) Complexes of amphotericin B and cholesteryl sulfate. J. Liposome Res. 3, 437-490.
97. Lasic, D.D. (1992) Mixed micelles in drug delivery. Nature 335, 279-280.
98. Fielding, R.M., Smith, P.C., Wang, L.H., Porter, J. and Guo, L.S.S. (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35, 1208-1213.
99. Wang, L.H., Fielding, R.M., Smith, P.C. and Guo, L.S.S. (1995) Comparative tissue distribution and elimination of amphotericin B-colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12, 275-283.
100. Fielding, R.M., Singer, A.W., Wang, L.H., Babbar, S. and Guo, L.S.S. (1992) Relationship of pharmacokinetics and drug distribution in tissues to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36, 299-307.
101. Sanders, S.W., Buchi, K.M., Goddard, M.S., Lang, J.K. and Tolman, K.G. (1991) Single dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to a healthy volunteer. Antimicrob. Agents Chemother. 35, 1029-1034.
102. Data on file, Sequus Pharmaceuticals Inc.
103. Bowdern, R. and Cays, M. (1992) Phase 1 study of amphotericin B colloidal suspension (ABCD) for the treatment of invasive fungal infection after marrow transplant. 32nd Intersci. Conf. Antimicrob. Agents Chemother. A621. American Society for Microbiology, Washington, DC.
104. Oppenheim, B.A., Herbrecht, R. and Kusne, S. (1995) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. 21. 1145-1153.
105. Cannon, R., Mamelok, R., Pietrelli, L. and Illmond, C. (1994) Renal sparing of amphotericin B colloidal dispersion (ABCD). 34th Intersci. Conf. Antimicrob. Agents Chemother, A103. American Society for Microbiology, Washington, DC.
106. Persson, U., Ragnarsson-Tennvall, G. and Anderson, S. (1992) Cost effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmaco. Econ. 2, 500-508.
107. Tollemar, J., Hockerstdet, K., Ericzon, B.G., Jalanko, H. and Ringden, O. (1995) Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 59, 45-50.
108. Tollemar, J. and Ringden, O. (1995) Lipid formulations of amphotericin B, Less toxicity but at what economic cost? Drug Safety 13, 207-218.
109. Kaplan, R.M. and Bush, J.W. (1982) Health related quality of life measurement for evaluation research and policy analysis, Health Psychol. 1, 61-80.
110. Juliano, R.L. and Lopez-Berestein, G. (1985) New lives for old drugs - Liposomal drug delivery systems reduce the toxicity but not the potency of certain chemotherapeutic agents. Pharm. Int. 6, 164-167.
111. Gregoriadis, G. and Florence, A.T. (1993) Liposomes in drug delivery. Drugs 45, 15-28.
112. Lasic, D.D. (1996) Liposomes - an industrial view. Chem. Ind. 210-214.
113. Scrip News (November 1995) Research and Development Pipeline.